Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: a retrospective case series.
BACKGROUND
Effective and tolerable treatment options for patients with dermatomyositis and polymyositis are limited. This retrospective case review describes treatment with adrenocorticotropic hormone (ACTH) gel in five patients who experienced a disease exacerbation and either failed or were unable to tolerate the side effects of previous therapy with steroids, intravenous immunoglobulins, and steroid-sparing drugs.


METHODS
Patients received ACTH gel subcutaneous injections of 80 U (1 mL) twice weekly (four patients) or once weekly (one patient) over the course of 12 weeks for short-term treatment of symptom exacerbations. Manual muscle testing using the Medical Research Council scale was assessed at baseline and at 3 months.


RESULTS
Improvement was seen in all patients, including improved muscle strength, decreased pain, and resolution of skin involvement. All patients tolerated the treatment well, and no significant side effects occurred.


CONCLUSIONS
The treatment of dermatomyositis and polymyositis is an approved use for ACTH gel, and these anecdotal reports would suggest consideration of ACTH gel as a therapeutic option. Further investigation is warranted.
Phoenix Neurological Associates, Phoenix, AZ, USA.
Todd
T
Levine
D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003882:Dermatomyositis / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005782:Gels; D006801:Humans; D007279:Injections, Subcutaneous; D008875:Middle Aged; D053580:Muscle Strength / Q000187:drug effects; D017285:Polymyositis / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies
D005782:Gels; D000324:Adrenocorticotropic Hormone